Trevena, Inc. To Host Analyst And Investor Day On October 28, 2015

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced that it will host an Analyst and Investor Day on Wednesday, October 28, 2015 in New York City. Presentations will begin at 12:00 p.m. Eastern Daylight Time and will be streamed simultaneously as a webcast. The event is expected to conclude by 3:00 p.m.

The presentations will focus on the Company’s clinical programs and will feature members of the Trevena management team and leading experts in acute heart failure and pain management, including:

• G. Michael Felker, M.D., M.H.S., Professor of Medicine and Chief of the Heart Failure Section at Duke University School of Medicine, and Director of Heart Failure Research at the Duke Clinical Research Institute;
• Peter Pang, M.D. M.Sc., Associate Professor of Emergency Medicine and Associate Director of Clinical Research, Indiana University;
• Neil Singla, M.D., Chief Scientific Officer, Lotus Clinical Research; and
• Lynn R. Webster, M.D., FACPM, FASAM, Vice President, Scientific Affairs, PRA Health Sciences; Past President, American Academy of Pain Medicine (AAPM).

To access the live audio webcast of the event, please visit the “Investors” section of the Company’s website at www.trevenainc.com. The webcast will be archived for 30 days after the event.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified – TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).